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Abstract We studied the effects of vitamin D3 metabolites on 
intracellular free Ca 2+ concentration ([Ca2+]i) and the respira- 
tory burst of monocyte-derived macrophages (MDM) from 
patients with vitamin D dependent rickets type II. Treatment 
of MDM from the patients and healthy donors with 1 nM 
1,25(OH)2D3 produced a rapid elevation of [Ca2+]i and similarly 
primed both types of cells for enhanced capacity for 0 2 release 
with phorbol diester. These results suggest that macrophages 
may have distinct non-genomic pathways of vitamin D3, which 
partly explain the absence of immunodeficiency and the 
disappearance of rickets after treatment with vitamin D3 in the 
patients. 
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VDR mutations in six Japanese patients and successfully 
treated them with massive doses of vitamin D3 [5]. They did 
not show any symptom of immunodeficiency. Furthermore, 
skeletal abnormality with total alopecia did not recur after 
the cessation of the therapy during 7-25 years of follow-up, 
despite their cells continuing to harbor the VDR mutation [6]. 
We preferentially used MDM from peripheral blood in this 
study, since 1,25(OH)2D3 is one of the inducers of differentia- 
tion of a monocyte-macrophage lineage and is also a potent 
activator for macrophage functions. The activation of macro- 
phages by 1,25(OH)2D3 results in enhanced capacity for pro- 
duction of microbicidal oxygen metabolites [8,9]. In this pa- 
per, we studied the effects of 1,25(OH)gD3 on calcium 
response and superoxide anion (O~-) release in MDM from 
patients with VDDR II to assess the role of VDR in macro- 
phage functions. 
I. Introduction 
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) is the major reg- 
ulator of calcium homeostasis and is now considered to be a 
true steroid hormone acting via intranuclear vitamin D recep- 
tor (VDR)-binding regulation of gene transcription [1]. This 
classical receptor-mediated pathway of 1,25(OH)2D3 action is 
not sufficient to account for all of the known effects of the 
seco-steroid. For example, 1,25(OH)2D3 rapidly stimulates 
Ca 2+ transport and cyclic guanosine monophosphate 
(cGMP) production in several cell systems, and some of these 
actions have been suggested to be independent of the genomic 
action [2]. In contrast, it was also reported that 1,25(OH)2D3 
did not produce rapid accumulation of cGMP in cells with 
deficient or mutant VDRs [3,4]. Thus, there is some contro- 
versy about the requirement of 1,25(OH)2D3 binding to the 
VDR in the initiation of these rapid effects. To address this 
question, we prepared blood monocyte-derived macrophages 
(MDM) from patients with vitamin D dependent rickets type 
II (VDDR II), who had already been characterized to have 
defects in VDR-mediated pathways [5 7], and studied the re- 
sponse of these cells to 1,25(OH)~D3. 
VDDR II consists of a spectrum of intracellular VDR de- 
fects and is characterized by the early onset of severe rickets 
and associated alopecia. Without treatment, patients suffer 
inanition, severe skeletal deformity, recurrent respiratory in- 
fections, and death by 8 years of age. We characterized the 
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2. Materials and methods 
2.1. Chemicals and media 
The vitamin D3 metabolites, 1,25(OH)2D3, 24,25(OH)2D3, 
25(OH)2D3, and 22-oxa-l,25(OH)2D3, were generous gifts from Chu- 
gai Pharmaceutical Co. (Tokyo). Stock preparations were dissolved 
and diluted in absolute thanol, and the concentration of the meta- 
bolites in each solution was verified by measuring the absorbance at 
264 nm. Solutions were made so as to keep the final concentration of
ethanol in the culture medium below 0.1% (v/v). Superoxide dismutase 
(SOD, from horse heart), ferricytochrome c, phorbol 12-myristate 13- 
acetate (PMA), and lipopolysaccharide (LPS, from Escheriehia coli K- 
235) were obtained from Sigma Chemical Co. (St. Louis, MO). Fura-2 
acetoxymethyl ester (fura-2/AM) was purchased from Dojin Chemical 
Co. (Tokyo). Dulbecco's modified Eagle's medium (DMEM) was 
from Flow Laboratories (McLean, VA). Hanks' balanced salt solution 
without phenol red (HBSS) was purchased from Nissui Pharmaceuti- 
cal Co. (Tokyo). All reagents to which MDM were exposed in culture 
were determined to be free from detectable LPS by the Limulus ameo- 
bocyte lysate assay (E-toxiate, Sigma). 
2.2. Preparation of monocyte-derived macrophages 
Two patients with VDDR II were subjected to this study. The 
clinical manifestation and identical point mutation in VDR cDNA 
were reported previously (patents 1 and 3 in [7]). We had already 
confirmed that neither binding activity of the VDRs to vitamin D 
responsive lement nor induction of 25(OH)D-24-hydroxylase with 
1,25(OHhD3 was observed in several types of cells from those pa- 
tients, and that these abnormalities still continued to be observed after 
treatment with vitamin D3 [10,11]. The two patients were treated with 
massive doses of vitamin D3 for 12 (patient 1) and 36 months (patient 
3), and the therapy had been discontinued for 6 (patient 1) and 10 
years (patient 3) without recurrence of any clinical skeletal symptom. 
The two patients were completely free from vitamin D3 treatment 
when they donated their peripheral blood for the present study. 
MDM were prepared by the method of Marodi et al. [12] with 
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minor modifications. Heparinized venous blood from healthy donors 
and the patients with VDDR II was overlaid on a density gradient 
medium composed of 1Y8% sodium metrizoate and dextran 500 with 
osmolality 460 mOsm (Nycomed Pharma, Oslo, Norway), and a 
mixed mononuclear layer was obtained by centrifugation at 450×g 
for 30 min [13]. After centrifugation and washes in DMEM, mono- 
nuclear cells were suspended in DMEM supplemented with 100 U/ml 
penicillin, 100 mg/ml streptomycin, and 10% heat-inactivated autolo- 
gous serum and adjusted to a final concentration of l X 10 ~ cell/ml. 
The cells were incubated in teflon beakers (Savillex, Minnetonka, 
MN) at 37°C in 5% CO2-95% air for 3 days. The cultured cells 
were detached by gentle pipetting and collected in centrifuge tubes. 
After washing twice with DMEM, the cells were cultured in DMEM 
on glass coverslips, placed in 35-mm diameter culture dishes, or in 24- 
well culture plates for 2 h, and then non-adherent cells were removed 
by vigorously washing with ice-cold saline. The adherent cell popula- 
tion contained > 85% macrophages by microscopic examination after 
Wright-Giemsa or esterase stain; other cells appeared to be lympho- 
cytes. Viability of the cells remained > 96% (trypan blue exclusion). 
2.3. Measurement of [Ca2+]i in single cells 
[Ca2+]i n single cells was determined by microfluorometry, as de- 
scribed previously [14]. Briefly, glass coverslips were placed in 35-ram 
diameter culture dishes. After culturing the MDM on the coverslips 
overnight in DMEM, they were incubated in the dark in DMEM 
containing 2.5 mM fura-2/AM and 1%, bovine serum albumin at 
37°C. After incubation for 20 min, the cells were washed four times 
with HBSS and then placed in a bath (volume 0.5 ml) on the stage of 
a fluorescence microscope (Optiphoto, Nikon) equipped with a photo- 
multiplier tube (R649; Hamamatsu Electronics, Shizuoka. Japan), a 
photon counter (545A; NF Circuit Design, Hiroshima, Japan), and 
an appropriate combination of filters (Nihon Shinkukogaku, Osaka, 
Japan), in which alternating excitation at wavelengths of 340 and 380 
nm was repeated. The solution (HBSS) at 37°C was continuously 
circulated at a rate of 1 ml/min. The intensity of emission at 510 
nm with excitation at 340 and 380 nm was monitored every 3 s. 
Absolute values of [Ca2+]~ were calculated by the method of Grynkie- 
wicz et ah [15] using a personal computer (NEC). 
2.4. Assay of 02 release 
The cells cultured in teflon beakers for 3 days were washed and 
resuspended in DMEM, and 1 × 106 cells were placed in each well of a 
24-well culture plate. After removal of non-adherent cells, MDM were 
cultured overnight in DMEM supplemented with 1 nM 1,25(OH)~D3 
or 50 ng/ml LPS or without any reagent. 02 release from MDM was 
assayed by measuring the SOD-inhibitable reduction of ferricyto- 
chrome c, corrected for the protein content, as described previously 
[161. 
3. Results 
3.1. Calcium response to vitamin D'3 metabolites in MDM.fi'om 
normal subjects 
Single cell analysis showed that the extent of calcium re- 
sponse to 1,25(OH)eD3 varied among the single cells. It has 
been shown that externally added ATP elicits the mobil ization 
of Ca 2+ in guinea pig peritoneal macrophages [17]. Addit ion 
of 0.3 M ATP induced rapid and transient elevation of 
Table 1 
Effect of 1,25(OH)7D3 on 0 2 release from MDM 
Treatment 0 2 generation (nmol/mg protein per h) 
Control MDM VDDR I1 MDM 
None 98 + 28 148 -+ 14 
LPS (50 ng/ml) 303 _+ 7 445 _+ 11 
1,25(OH)2D3 (1 nM) 244 + 28 377 -+ 31 
MDM were untreated or treated overnight with 50 ng/ml LPS or 1 nM 
1,25(OH)2D3. O~- release of MDM stimulated by 500 ng/ml was 
measured by the SOD-inhibitable reduction of ferricytochrome e, as 
described previously [16]. Values are mean _+ S.D., n = 5. 
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[Ca2+]i, as shown in Fig. 1A. Therefore, ATP was always 
used as a positive control for calcium response, and data 
from cells unresponsive to ATP  were omitted. The final con- 
centrat ion of ethanol in the circulating medium was less than 
0.1%, at which concentrat ions ethanol did not promote any 
[Ca2+]i change in MDM.  
Exposure of MDM from normal subjects to 1 nM 
1,25(OH)2D3 rapidly increased [Ca2+]i from the basal level 
of 209+5 nM (mean+ S.D., n=5)  to 413+23 nM (n--5). A 
typical response is shown in Fig. 1A. Both ATP- and 
1,25(OH)2D3-induced increases of [Ca2+]i were almost com- 
pletely inhibited when extracellular Ca 2+ was removed with 
EDTA (Fig. 1B), indicating that these agents evoke extracel- 
lular Ca 2+ influx across the plasma membrane. 
MDM from healthy volunteers imilarly responded to other 
vitamin D3 metabolites with various affinities to VDR and 
rapidly increased [Ca2+]i, as shown in Fig. 1C-E. Exposure 
to 1 nM 25(OH)D3, 24,25(OH)2D3, or 22-oxa-l,25(OH)2D3 
increased [Ca2+]i to a maximum level of 416+21 (n=5) ,  
310 + 30 (n = 51, or 349 + 32 nM (n = 5), respectively, suggest- 
ing that the calcium response might not be mediated by VDR. 
3.2. F~ff'ect of 1,25(OH)2D3 on calcium response of MDM 
from patients with VDDR H 
When MDM,  prepared from patients with VDDR II, were 
treated with 1 nM 1,25(OH)2D3, they also responded to 
1,25(OH)2D3 and rapidly increased [Ca2+]i to a maximum 
level of 408 + 47 nM (n = 5), thus demonstrat ing that VDR- 
dependent processes may not be necessary to evoke the cal- 
cium transient (Fig. 1F). 
3.3. Eff'ect of 1,25(OH)eD3 on 0 2 release of MDM from 
patients with VDDR H 
In response to bacterial LPS or cytokines, macrophages 
markedly enhance their capacity for production of oxygen 
intermediates, which have been postulated to play a central 
role in microbicidal and cytocidal activities. When MDM 
were prepared and cultured under LPS-free conditions, they 
were quiescent; control MDM released 98 + 28 (mean + SD. ,  
n = 5) nmol O2/mg protein per h with PMA (Table 1). This 
value increased about 3-fold after treatment with LPS. Treat- 
ment of control MDM with 1,25(OH)2D3 also augmented the 
release similarly with LPS. MDM from the patients with 
VDDR II responded to LPS and increased the amount  of 
()~ release. Furthermore,  these cells were also primed by 
1,25(OH)2D~ for enhanced capacity for 0 2 release with 
PMA, suggesting that macrophages defective in VDR func- 
tions have distinct non-genomic pathways that promote func- 
tional activation of macrophages in response to 1,25(OH)eD3. 
4. Discussion 
Vitamin D:~ exerts its biological action through binding to 
its nuclear receptor, VDR,  that activates the transcription of 
target genes. In addit ion to this classical genomic action, vi- 
tamin D3 has been suggested to have distinct non-genomic 
pathways. 1,25(OH)2D3 can rapidly induce phosphoinosit ide 
breakdown, activation of several enzymes, Ca 2t mobil ization, 
and accumulation of cGMP in multiple tissues [2]. These rap- 
id actions have been postulated to be non-genornic actions of 
1,25(OH)2D3 [2]. The [Ca2+]i is a critically important  intra- 
cellular messenger for regulating cellular functions [18]. 
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Fig. I. Effect of vitamin D3 metabolites on [Ca2+]i in single MDM. 
MDM were prepared from healthy donors (A E) or patients with 
VDDR II (F) and attached on glass coverslips as described in Sec- 
tion 2. The fura-2/AM-loaded cells were placed on a bath on the 
stage of a fluorescence microscope. Cells were first stimulated by 0.3 
M ATP and then exposed to 1 nM 1,25(OH)2D3 (A,B,F), 1 nM 22- 
oxa-l,25(OH)2D3 (C), 1 nM 24,25(OH)2D3 (D), or 1 nM 25(OH)D3 
(E). In B, ATP and 1,25(OH)2D3 were added in the presence of 1.5 
mM EDTA. Circulation of HBSS containing ATP or one of the vi- 
tamin D3 metabolites was started at the times indicated by the ar- 
rows. Medium containing the stimulants reached the bath at 1 min. 
Changes in [Ca2+]i were measured as described in Section 2. Results 
shown are representative of those in 5 separate experiments. 
1,25(OH)2Da increased [Ca2+]i by stimulating influx of extra- 
cellular Ca 2+ in both osteoblastic ROS 17/2.8 cells and ROS 
24/1 cells, in the presence and absence of VDR, respectively 
[19], suggesting that the calcium transient induced by 
1,25(OH)2Da is independent of VDR. In the human bipoten- 
tial leukemic ell line, HL-60, 1,25(OH)2D3 evoked a calcium 
transient, but its synthetic analogue (lc~,313,5Z,7E)-9,10-seco- 
cholesta-5,7,10(19)-triene- 1,3,25-triol (22-oxa-l,25(OH)2D3) 
did not [20]. However, as shown in Fig. 1, normal macro- 
phages derived from blood monocytes imilarly responded 
to various vitamin Da metabolites (1,25(OH)2Da, 
24,25(OH)2Da, 25(OH)2Da, 22-oxa-l,25(OH)2Da) and showed 
the same time course of [Ca2+]i rise immediately after expo- 
sure to these agents, whereas each affinity of vitamin D me- 
tabolites for VDR is markedly different. Furthermore, MDM 
from patients with VDDR II showed a rapid elevation of 
[Ca2+]i, which was identical to that of control MDM. These 
results upport he concept that 1,25(OH)2D3-induced calcium 
response is not mediated by VDR. 
Civitelli et al. [19] and Farach-Carson et al. [21] have sug- 
gested the existence of a plasma membrane receptor for 
1,25(OH)2D3 that is distinct from the traditional VDR. How- 
ever, the receptor has not yet been characterized, and several 
investigators suggested that some of the rapid effects of 
1,25(OH)2D3 may be mediated by the VDR [3,4]. 
Macrophages play a central role in defense against micro- 
bial infection by presenting antigen to lymphocytes during the 
development of specific immunity and by serving as accessory 
cells to lymphocytes. Macrophages also carry out fundamen- 
tal protective functions in ingesting and killing invading 
organisms. In this study, we examined the effects of 
1,25(OH)2D3 preferentially on macrophages, since 
1,25(OH)2D3 is known as an inducer of differentiation of a 
monocyte-macrophage lin age and a potent activator of 
macrophage functions [22-25]. 1,25(OH)2D3 enhances the 
competence of MDM for secretion of oxygen intermediates 
and dramatically augments the microbicidal and tumoricidal 
activity of these cells [24]. These actions of 1,25(OH)2D3 have 
been suggested to be mediated by VDR. When normal MDM 
were treated overnight with 1,25(OH)2D3 or LPS, they appar- 
ently augmented the capacity for 0 2 release stimulated by 
PMA. MDM from patients with VDDR II were similarly 
activated after treatment overnight with 1,25(OH)2D3 or 
LPS, thus demonstrating that MDM from patients with 
VDDR II exhibit normal respiratory burst activity, and sug- 
gesting that the priming of MDM for enhanced capacity of 02 
release by 1,25(OH)2D3 could be induced in the absence of 
VDR action. 
Children with vitamin D deficiency appear to have a high 
incidence of infection [26], and vitamin D-deficient rat macro- 
phages showed abnormalities in phagocytic and microbicidal 
activities [27], suggesting that vitamin D is one of the impor- 
tant factors for defense against microbial infection. However, 
our patients with VDDR II did not show any recurrent infec- 
tion throughout their lives, and MDM from these patients 
normally responded to 1,25(OH)2D3. These findings indicate 
that macrophages are able to exhibit distinct non-genomic 
actions and/or to compensate VDR actions by other nuclear 
signaling pathways, which may, at least in part, maintain their 
functions in the absence of VDR-mediated pathways, and 
may explain the absence of immunodeficiency in the patients 
with VDDR II. 
In our patients with VDDR II, severe rickets, alopecia, and 
muscular weakness manifesting before treatment completely 
improved with massive doses of vitamin D3 except for total 
alopecia [5]. Furthermore, rickets did not recur after cessation 
of the therapy for 7-15 years of follow up, although their cells 
still continued to exhibit a genetic defect [6]. These clinical 
findings strongly suggest hat the treatment with vitamin D3 
up-regulates non-genomic pathways of vitamin D3 and/or a 
VDR-independent uclear signaling bypass, i.e. via other ster- 
oid receptors including retinoid receptors and retinoid X re- 
ceptors, to compensate the VDR actions. To address this 
question, we are currently studying the changes in vitamin 
D3 responses of MDM from patients freshly diagnosed as 
VDDR II before and after long-term treatment with massive 
doses of vitamin D3. 
Differentiation of mononuclear phagocytes into osteoclasts 
is also stimulated by 1,25(OH)2D3 via a mechanism involving 
osteoblastic cells [28]. However, since VDR is present in os- 
teoblasts but not in osteoclasts [28], the present findings in- 
dicate that non-genomic actions of vitamin D3 might be an 
important subject o study for understanding the bone forma- 
tion and remodeling in patients with VDDR II. 
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